In this multicenter , randomized , open-label , active-comparator , phase 3 trial , 92 patients were randomized 2:1 to receive edoxaban 30mg once daily ( n = 62 ) or enoxaparin sodium ( enoxaparin ) 2000IU ( equivalent to 20mg ) twice daily ( n = 30 ) for 11 to 14days .